1033810-14-8 Usage
Description
Benzenamine, 3-chloro-4-(1H-indazol-4-yloxy)-, also known as AG-120, is a potent indazole derivative that functions as a specific inhibitor of the isocitrate dehydrogenase 1 (IDH1) enzyme. This enzyme is integral to cellular metabolism, and its mutation is implicated in the development of certain cancers. AG-120's mechanism of action is to block the activity of the mutant IDH1, thereby reducing the production of the oncometabolite 2-hydroxyglutarate, which is a key contributor to tumorigenesis.
Uses
Used in Oncology:
Benzenamine, 3-chloro-4-(1H-indazol-4-yloxy)is used as a targeted therapy for the treatment of cancers with IDH1 mutations. Its application is particularly relevant for malignancies such as acute myeloid leukemia and other solid tumors, where the presence of mutant IDH1 enzymes can drive cancer progression. By inhibiting the mutant IDH1 enzyme, AG-120 aims to restore normal cellular metabolism and reduce the oncogenic effects of 2-hydroxyglutarate.
Used in Pharmaceutical Research and Development:
In the pharmaceutical industry, Benzenamine, 3-chloro-4-(1H-indazol-4-yloxy)is utilized in the ongoing research and development of novel cancer therapies. Its role in preclinical and clinical studies is to evaluate its efficacy and safety as a potential drug candidate for IDH1-mutated cancers, contributing to the advancement of precision medicine in oncology.
Used in Drug Discovery for Metabolic Enzyme Inhibition:
Benzenamine, 3-chloro-4-(1H-indazol-4-yloxy)is also used in drug discovery efforts focused on the inhibition of metabolic enzymes implicated in cancer. Its development and study provide insights into the role of metabolic pathways in tumorigenesis and the potential of enzyme inhibition as a therapeutic strategy.
The provided materials do not specify different applications in various industries outside of oncology and pharmaceutical research and development. Therefore, the uses listed are focused on these areas where AG-120 has demonstrated potential based on the information given.
Check Digit Verification of cas no
The CAS Registry Mumber 1033810-14-8 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,3,3,8,1 and 0 respectively; the second part has 2 digits, 1 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 1033810-14:
(9*1)+(8*0)+(7*3)+(6*3)+(5*8)+(4*1)+(3*0)+(2*1)+(1*4)=98
98 % 10 = 8
So 1033810-14-8 is a valid CAS Registry Number.
1033810-14-8Relevant articles and documents
Design and synthesis of pyrrolo[3,2- d ]pyrimidine human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) dual inhibitors: Exploration of novel back-pocket binders
Kawakita, Youichi,Banno, Hiroshi,Ohashi, Tomohiro,Tamura, Toshiya,Yusa, Tadashi,Nakayama, Akiko,Miki, Hiroshi,Iwata, Hidehisa,Kamiguchi, Hidenori,Tanaka, Toshimasa,Habuka, Noriyuki,Sogabe, Satoshi,Ohta, Yoshikazu,Ishikawa, Tomoyasu
, p. 3975 - 3991 (2012/07/16)
To develop novel human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) kinase inhibitors, we explored pyrrolo[3,2-d]pyrimidine derivatives bearing bicyclic fused rings designed to fit the back pocket of the HER2/EGFR proteins. Among them, the 1,2-benzisothiazole (42m) ring was selected as a suitable back pocket binder because of its potent HER2/EGFR binding and cell growth inhibitory (GI) activities and pseudoirreversibility (PI) profile as well as good bioavailability (BA). Ultimately, we arrived at our preclinical candidate 51m by optimization of the N-5 side chain to improve CYP inhibition and metabolic stability profiles without a loss of potency (HER2/EGFR inhibitory activity, IC50, 0.98/2.5 nM; and GI activity BT-474 cells, GI50, 2.0 nM). Reflecting the strong in vitro activities, 51m exhibited potent tumor regressive efficacy against both HER2- and EGFR-overexpressing tumor (4-1ST and CAL27) xenograft models in mice at oral doses of 50 mg/kg and 100 mg/kg.
